. Author manuscript; available in PMC: 2021 Apr 14.

Published in final edited form as: Hematol Med Oncol. 2019 Jun 28;4:1000183. doi: 10.15761/hmo.1000183

Table 3. Drugs currently under clinical trials.

Name	Composition		Disease	Clinical trial.gov identifier (Phase)	References
Name	NPs	Active substances	Disease	Clinical trial.gov identifier (Phase)	References
ABI-011	Albumin	Thiocolchicine analog	Lymphoma	NCT02582827 (I) NCT01163071 (i)	[184]
AZD2811	Polymers	Aurora B kinase inhibitor	Acute myeloid leukemia	NCT03217838 (I, II)	[109,185]
BP1001	Liposomes	Growth factor receptor bound protein-2 antisense oligonucleotide	Leukemia	NCT02923986 (I, II) NCT02781883 (II) NCT01159028 (I)	[186–188]
DCR-MYC	Liposomes	DsiRNA for MYC oncogene silencing	Multiple myeloma and lymphoma	NCT02110563 (I)	[189,190]
JVRS-100	Liposomes	Plasmid DNA complex	Leukemia	NCT00860522 (I)	[191]
Mitoxantrone hydrochloride liposome	Liposomes	Mitoxantrone	Leukemias and lymphoma	NCT02043756 (I) NCT02131688 (I) NCT02856685 (I, II) NCT03776279 (II) NCT02595242 (I) NCT02597387 (II) NCT02597153 (II) NCT02879643 (I) NCT02518750 (II) NCT02733380 (II) NCT02724163 (III) NCT03591510 (II)	[192–194]
NC-4016 DACH-Platin micelle	Polyamino acid and PEG	Oxaliplatin	Lymphoma	NCT03168035 (I)	[195]
PNT2258	Liposomes	Single-stranded DNAi	Lymphoma	NCT02378038 (II) NCT02226965 (II) NCT01733238 (II) NCT01191775 (I)	[196–198]